If you've spent any time on LinkedIn, TikTok, or Reddit lately, you've seen it: peptides are having a moment. Consumer interest is up 20x year-over-year. Search interest in “peptide therapy” is up 459% on TikTok alone. And by the end of the month, the conversation is about to get a lot more concrete.

On July 23–24, the FDA's Pharmacy Compounding Advisory Committee (PCAC) meets to formally review seven peptides for possible return to the 503A Bulks List: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and Emideltide (DSIP). It's the biggest regulatory moment this category has had since these substances were restricted in 2023, and it's worth understanding exactly what it does, and doesn't, mean.

What a PCAC meeting actually is

The Pharmacy Compounding Advisory Committee is an independent panel the FDA consults before changing a substance's compounding status. Its recommendations are non-binding. A favorable outcome starts a formal FDA review process, it is not an approval, and it doesn't make anything legally compoundable on its own.

The three-category system, in plain terms

• Category 1: under evaluation. The FDA exercises enforcement discretion, effectively permitting compounding while review continues.
• Category 2: significant safety concerns identified. Not permitted for compounding. Most of the peptides under review this month were moved here in 2023.
• Category 3: nominated without adequate support. Also not permitted.

Why “reclassified” doesn't mean “ready to prescribe”

Even in the best-case outcome — all seven peptides move back to Category 1 — some hard requirements stand between that announcement and a compliant prescription including the grade of the active pharmaceutical ingredient. Compounders can't legally use research-use-only (RUO) bulk drug substances. Right now, the bulk substances for these peptides exist almost exclusively in RUO form.

Where CareValidate stands

CareValidate is built to be the compliance and clinical backbone for peptide programs, ready to move the moment pharmacies have compliant supply in place. We’re working on the backend to set this up operationally, and we're tracking this process closely, and we'll tell our partners the moment there's something real to act on.

What we offer today

Our current longevity and peptide formularies are unaffected by this meeting's outcome, in either direction: NAD+ (injection, oral, nasal spray), Sermorelin (oral, injection), GHK-Cu (topical), PT-141 (injection), and Glutathione (injection). All LegitScript-certified and fully operational.

What's next

We'll update this post directly once the PCAC recommendation is public. In the meantime, if you're building a longevity and peptide program, or trying to figure out what building one compliantly actually requires , our Peptide Playbook walks through the full regulatory, clinical, and business picture, and our team is happy to talk through what a compliant program looks like for your patient base.

Read the playbook here >>

Book a demo here >>